The approval of this drug includes the use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who received treatment of at least one prior systemic therapy [164]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.